ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Sandoz seeks EMA approval for EirGenix’s trastuzumab biosimilar
December 24, 2021Trastuzumab is a monoclonal antibody intended to treat human epidermal growth factor receptor 2 positive (HER2-positive) breast and metastatic gastric cancers. -
Positive Phase III Clinical Results for EirGenix's Proposed Trastuzumab Biosimilar
March 25, 2021In a press conference today, EirGenix, Inc. announced that the Phase III clinical trial (Trial No.: EGC002, NCT03433313) of its breast cancer biosimilar, EG12014 (proposed trastuzumab biosimilar, also called EGI014), has met its primary endpoint. -
Sandoz signs cancer drug deal with EirGenix
May 05, 2019Sandoz has signed an agreement with EirGenix for the commercialisation of a trastuzumab biosimilar.
Pharma Sources Insight January 2025
